Tags

Type your tag names separated by a space and hit enter

The association of the R563Q genotype of the ENaC with phenotypic variation in Southern Africa.
Am J Hypertens. 2012 Dec; 25(12):1286-91.AJ

Abstract

BACKGROUND

The epithelial sodium channel (ENaC) may be a common underlying pathway for the development of primary hypertension. In South Africa, the R563Q variant of the ENaC is associated with low-renin-low-aldosterone hypertension and preeclampsia in black Africans and mixed-ancestry peoples. The purpose of this study was to investigate the prevalence of the R563Q variant in the multiethnic populations of South Africa, its association with hypertension and response to amiloride in patients with resistant hypertension.

METHODS

Samples were obtained from hypertensives and normotensive controls in Cape Town and Johannesburg, and unselected San living in the rural areas of the Northern Cape and Namibia. Resistant hypertensives with the R563Q variant were treated with amiloride.

RESULTS

One thousand nine hundred and thirty nine (1,468 hypertensives, 471 controls) subjects were recruited. Eighty-seven (5.9%) of the hypertensives were R563Q heterozygote vs. 8 (1.7%) of the normotensives (P < 0.0005). In the Namibian and Northern Cape San 19.5% and 18.8% of subjects were R563Q positive. There was no association with hypertension. Spot sodium excretion was lower in the San compared to urban subjects (7.3 vs. 12.2 mmol/mmol, P = 0.016). Twenty-two R563Q heterozygote patients with resistant hypertension received amiloride with a mean reduction in blood pressure (BP) of 36/17 mm Hg (P < 0.0001).

CONCLUSIONS

The R563Q variant is strongly associated with hypertension in urban areas in South Africa. The San are the likely origin of the variant, but it is not associated with hypertension, presumably due to their lower sodium intake. Screening patients with resistant hypertension in South Africa for the R563Q variant provides a feasible pharmacogenetic approach to treatment.

Authors+Show Affiliations

Division of Nephrology and Hypertension, Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa. swjones@gmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22895453

Citation

Jones, Erika S W., et al. "The Association of the R563Q Genotype of the ENaC With Phenotypic Variation in Southern Africa." American Journal of Hypertension, vol. 25, no. 12, 2012, pp. 1286-91.
Jones ES, Owen EP, Rayner BL. The association of the R563Q genotype of the ENaC with phenotypic variation in Southern Africa. Am J Hypertens. 2012;25(12):1286-91.
Jones, E. S., Owen, E. P., & Rayner, B. L. (2012). The association of the R563Q genotype of the ENaC with phenotypic variation in Southern Africa. American Journal of Hypertension, 25(12), 1286-91. https://doi.org/10.1038/ajh.2012.125
Jones ES, Owen EP, Rayner BL. The Association of the R563Q Genotype of the ENaC With Phenotypic Variation in Southern Africa. Am J Hypertens. 2012;25(12):1286-91. PubMed PMID: 22895453.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The association of the R563Q genotype of the ENaC with phenotypic variation in Southern Africa. AU - Jones,Erika S W, AU - Owen,E Patricia, AU - Rayner,Brian L, Y1 - 2012/08/16/ PY - 2012/8/17/entrez PY - 2012/8/17/pubmed PY - 2013/5/15/medline SP - 1286 EP - 91 JF - American journal of hypertension JO - Am J Hypertens VL - 25 IS - 12 N2 - BACKGROUND: The epithelial sodium channel (ENaC) may be a common underlying pathway for the development of primary hypertension. In South Africa, the R563Q variant of the ENaC is associated with low-renin-low-aldosterone hypertension and preeclampsia in black Africans and mixed-ancestry peoples. The purpose of this study was to investigate the prevalence of the R563Q variant in the multiethnic populations of South Africa, its association with hypertension and response to amiloride in patients with resistant hypertension. METHODS: Samples were obtained from hypertensives and normotensive controls in Cape Town and Johannesburg, and unselected San living in the rural areas of the Northern Cape and Namibia. Resistant hypertensives with the R563Q variant were treated with amiloride. RESULTS: One thousand nine hundred and thirty nine (1,468 hypertensives, 471 controls) subjects were recruited. Eighty-seven (5.9%) of the hypertensives were R563Q heterozygote vs. 8 (1.7%) of the normotensives (P < 0.0005). In the Namibian and Northern Cape San 19.5% and 18.8% of subjects were R563Q positive. There was no association with hypertension. Spot sodium excretion was lower in the San compared to urban subjects (7.3 vs. 12.2 mmol/mmol, P = 0.016). Twenty-two R563Q heterozygote patients with resistant hypertension received amiloride with a mean reduction in blood pressure (BP) of 36/17 mm Hg (P < 0.0001). CONCLUSIONS: The R563Q variant is strongly associated with hypertension in urban areas in South Africa. The San are the likely origin of the variant, but it is not associated with hypertension, presumably due to their lower sodium intake. Screening patients with resistant hypertension in South Africa for the R563Q variant provides a feasible pharmacogenetic approach to treatment. SN - 1941-7225 UR - https://www.unboundmedicine.com/medline/citation/22895453/The_association_of_the_R563Q_genotype_of_the_ENaC_with_phenotypic_variation_in_Southern_Africa_ L2 - https://academic.oup.com/ajh/article-lookup/doi/10.1038/ajh.2012.125 DB - PRIME DP - Unbound Medicine ER -